Terray Therapeutics, a Los Angeles, CA-based biotechnology company focused on small molecule drug discovery and development, received an investment from NVentures, NVIDIA’s venture capital arm.
Additional financing included a syndicate of new and existing institutional investors, including John Maraganore, founding Chief Executive Officer of Alnylam Pharmaceuticals, and Bassil Dahiyat, founder and Chief Executive Officer of Xencor.
The amount of the deal was not disclosed.
Led by Jacob Berlin, Ph.D., CEO, Terray is a biotechnology company that leverages technology, and data, to discover and develop small molecule therapeutics. The company explores molecules and targets with a sophisticated integration of throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Its platform combines experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges.
Terray will leverage NVIDIA DGX™ Cloud to develop the world’s most comprehensive chemistry foundation models for small molecules, some of which will be available on the NVIDIA BioNeMo™ cloud service for generative AI in drug discovery. Tapping into the NVIDIA AI software stack and NVIDIA’s full-stack computing expertise will help the company optimize and scale the development of its foundation models. These developments will allow Terray to leverage its proprietary experimental datasets to create ligand-based and structure-based models to further propel its pipeline into the clinic.
FinSMEs
10/11/2023